Vanguard Capital Management’s Pacific Biosciences PACB Stock Holding History
Bought
Maintained
Sold
Other funds holding PACB
Vanguard Capital Management's PACB Position: Q3 2026 in Review
Vanguard Capital Management reduced its Pacific Biosciences (PACB) stake by 1.2% in Q3 2026, selling an estimated $223K and leaving 13,239,670 shares worth $31.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2154.
Vanguard Capital Management first reported a position in PACB in Q1 2026 and has held it in 3 quarters since. 204 funds tracked by Wall St. Rank hold PACB as of Q3 2026.
- Vanguard Capital Management held 13,239,670 shares of Pacific Biosciences worth $31.4M as of Q3 2026.
- Vanguard Capital Management sold 158,264 Pacific Biosciences shares in Q3 2026, an estimated $223K.
- Pacific Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2154 holding.
- Vanguard Capital Management first reported a position in Pacific Biosciences in Q1 2026 and has held it in 3 quarters since.
- 204 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.